Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer, Carcinoma
Trial Timeline
Nov 1, 2015 → Mar 17, 2021
NCT ID
NCT02592577About Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T is a phase 1 stage product being developed by Adaptimmune Therapeutics for Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02592577. Target conditions include Non-Small Cell Lung Cancer, Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02592577 | Phase 1 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer